Needham & Company
-
Dyax Announces Proposed Public Offering of 7,000,000 Shares of Common Stock
-
Dyax Corp. (DYAX) PT Raised to $30 at Needham & Company
-
Notable Analyst Rating Changes 03/25: (SOL) (RAX) (PCAR) Upgraded; (HIMX) (PHM) (ACI) Downgraded
-
Dyax (DYAX) Prices 8M Common Offering at $9.25/Share
-
Eli Lilly (LLY) Ramucirumab Data a Positive for Dyax (DYAX), Needham & Company Says
-
Dyax Corp. (DYAX) Target Lifted to $13 at Needham & Company on DX2930 Potential
-
Dyax (DYAX) Announces Common Stock Offering
-
Dyax (DYAX) a Buy on Franchise and Pipeline Optimism
-
Needham & Company Maintains a 'Buy' on Dyax Corp. (DYAX); Strong Kalbitor Growth Trends
-
Needham & Company Starts Dyax Corp. (DYAX) at Buy; Returning to Investor Radar as Kalbitor Grows
-
Needham & Company Maintains a 'Buy' on Dyax Corp. (DYAX); Summer Brings Rising Temperatures Along with Rising Revenues
-
Needham & Company Reiterates a 'Buy' on Dyax Corp. (DYAX); Expand Current KALBITOR Commercialization Agreement to Include Latin America and Southeast Asia
-
Needham & Company Reiterates a 'Buy' on Dyax (DYAX); L-T Sales Challenges, But Growth Potential
-
Needham & Company Reiterates a 'Buy' on Dyax Corp. (DYAX); The Company Continues to Focus on Building the Patient Base in HAE Orphan Indication For Long-Term Revenue Generation;
-
Needham & Company Reiterates a 'Buy' on Dyax (DYAX); Company Remains Focused on Building Steadily Growing Patient Base
-
Needham & Company Reiterates a 'Buy' Rating on Dyax (DYAX); Three Building Blocks For Growth
-
Dyax (DYAX) Prices 17M Common Offering at $3.25/Share
-
Dyax Corp. (DYAX) Announces Common Offering
-
Needham Lifts Price Target on Dyax (DYAX) to $8
-
Needham & Co Upgrades Dyax (DYAX) to Buy
-
Needham & Co Downgrades Dyax Corp. (DYAX) to Hold

